Research programme: microbiome-based therapeutics - Ferring Pharmaceuticals/MyBiotics/Rebiotix
Latest Information Update: 18 Feb 2021
At a glance
- Originator Ferring Pharmaceuticals; MyBiotics; Rebiotix
- Class Bacteria
- Mechanism of Action Bacteria replacements; Vaginal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Bacterial vaginosis
Most Recent Events
- 17 Feb 2021 Ferring, Rebiotix, and MyBiotics agree to co-promote and co-develop microbiome-based gynaecological disorder therapeutics in USA, Switzerland, Israel for bacterial vaginosis
- 17 Feb 2021 Early research in Bacterial vaginosis in Switzerland, USA, Israel (unspecified route) in February 2021